173 related articles for article (PubMed ID: 36945359)
1. An
Özbek M; Toy HI; Oktay Y; Karakülah G; Suner A; Pavlopoulou A
PeerJ; 2023; 11():e15096. PubMed ID: 36945359
[TBL] [Abstract][Full Text] [Related]
2. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.
Wu S; Miao K; Wang L; Ma Y; Wu X
Med Oncol; 2022 Jan; 39(2):27. PubMed ID: 35018510
[TBL] [Abstract][Full Text] [Related]
4. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
5. The promising novel biomarkers and candidate small molecule drugs in lower-grade glioma: Evidence from bioinformatics analysis of high-throughput data.
Zhang B; Wu Q; Xu R; Hu X; Sun Y; Wang Q; Ju F; Ren S; Zhang C; Qi F; Ma Q; Wang Z; Zhou YL
J Cell Biochem; 2019 Sep; 120(9):15106-15118. PubMed ID: 31020692
[TBL] [Abstract][Full Text] [Related]
6. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
7. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
8. Identification of Hub Genes of Mesio Temporal Lobe Epilepsy and Prognostic Biomarkers of Brain Low-grade Gliomas Based on Bioinformatics Analysis.
Xu J; Sun M; Wang Y; Xie A; Gao J
Cell Transplant; 2020; 29():963689720978722. PubMed ID: 33327771
[TBL] [Abstract][Full Text] [Related]
9. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
10. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
11. New biomarker: the gene HLA-DRA associated with low-grade glioma prognosis.
Chen D; Yao J; Hu B; Kuang L; Xu B; Liu H; Dou C; Wang G; Guo M
Chin Neurosurg J; 2022 May; 8(1):12. PubMed ID: 35585639
[TBL] [Abstract][Full Text] [Related]
12. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
Lin WW; Ou GY; Zhao WJ
J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
[TBL] [Abstract][Full Text] [Related]
13. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Bioinformatics Analysis of mRNA Expression Profiles and Identification of a miRNA-mRNA Network Associated with the Pathogenesis of Low-Grade Gliomas.
Wang M; Cui Y; Cai Y; Jiang Y; Peng Y
Cancer Manag Res; 2021; 13():5135-5147. PubMed ID: 34234557
[TBL] [Abstract][Full Text] [Related]
15. Identification of genes related to low-grade glioma progression and prognosis based on integrated transcriptome analysis.
Jiang Y; He J; Guo Y; Tao H; Pu F; Li Y
J Cell Biochem; 2020 Jun; 121(5-6):3099-3111. PubMed ID: 31886582
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
17. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
Vachher M; Arora K; Burman A; Kumar B
J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
[TBL] [Abstract][Full Text] [Related]
18. Use of Genome-Scale Integrated Analysis to Identify Key Genes and Potential Molecular Mechanisms in Recurrence of Lower-Grade Brain Glioma.
Deng T; Gong YZ; Wang XK; Liao XW; Huang KT; Zhu GZ; Chen HN; Guo FZ; Mo LG; Li LQ
Med Sci Monit; 2019 May; 25():3716-3727. PubMed ID: 31104065
[TBL] [Abstract][Full Text] [Related]
19. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
20. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
